Handel nachbörslich: 1.38

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten

NeuroSense Embarks on HIPAA Compliance Journey - TipRanks

NeuroSense Therapeutics Ltd: -52.36% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle

NeuroSense Reports Positive Drug Study Results - TipRanks

NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.9% - Defense World

It would be worthwhile to take a closer look at NeuroSense Therapeutics Ltd (NRSN) - US Post News

Lonza, NeuroSense Enter Alliance For ALS Candidate - Contract Pharma

NeuroSense Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks

NeuroSense faces Nasdaq delisting over share price By Investing.com - Investing.com UK

NeuroSense faces Nasdaq delisting over share price By Investing.com - Investing.com Canada

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification - PR Newswire

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification - StockTitan

Ratio Examination: NeuroSense Therapeutics Ltd (NRSN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

NeuroSense Therapeutics Ltd: Navigating Market Fluctuations with a 13.81M Market Cap - The InvestChronicle

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Sees Significant Decline in Short Interest - Defense World

NeuroSense Eyes Lucrative Pharma Partnerships for ALS Drug - TipRanks

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug - Yahoo Finance

NeuroSense Therapeutics Gains Nasdaq Extension - TipRanks

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences - GuruFocus.com

NeuroSense to Participate in Upcoming ALS Conferences: European - GuruFocus.com

NeuroSense Completes Dosing of Last Patient in the Double-Blind - GuruFocus.com

NeuroSense Therapeutics Announces Share Issuance - TipRanks

NeuroSense Therapeutics (NASDAQ:NRSN) Trading 5.7% Higher - Defense World

Neurosense Therapeutics Ltd expected to post a loss of 20 cents a shareEarnings Preview - XM

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price - The Malaysian Reserve

NeuroSense secures $600,000 in private placement - Investing.com

NeuroSense secures $600,000 in private placement By Investing.com - Investing.com Canada

Amyotrophic Lateral Sclerosis Pipeline 2024: Clinical Trials - openPR

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price - PR Newswire

NeuroSense Therapeutics Announces Strategic Securities Sale - TipRanks

Stock Market Recap: NeuroSense Therapeutics Ltd (NRSN) Concludes at 0.68, a -10.50 Surge/Decline - The Dwinnex

New biomarker data supports NeuroSense’s ALS drug - Yahoo Finance

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial - The Malaysian Reserve

NeuroSense Therapeutics Ltd (NRSN) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

NeuroSense reports positive ALS trial results, plans phase 3 By Investing.com - Investing.com Canada

Edgewise Therapeutics Inc Inc. (EWTX) Price Performance: The Role of Supply and Demand - The InvestChronicle

NRSN’s price-to-sales ratio: Is it a good investment opportunity? - US Post News

NeuroSense reports positive ALS trial results, plans phase 3 - Investing.com

NeuroSense’s ALS Drug Shows Promise in Trial - TipRanks

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial - PR Newswire

NRG Energy Inc. (NRG) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial - StockTitan

AC Immune bags FDA fast track designation - European Biotechnology News

Amyotrophic Lateral Sclerosis Treatment Market size is set to grow by USD 663.7 million from 2024-2028, Increase in incidence and prevalence of amyotrophic lateral sclerosis to boost the market growth, Technavio - The Malaysian Reserve

Amyotrophic Lateral Sclerosis Treatment Market size is set to grow by USD 663.7 million from 2024-2028, Increase in incidence and prevalence of amyotrophic lateral sclerosis to boost the market growth, Technavio - PR Newswire

Amyotrophic Lateral Sclerosis Treatment Market size is set to grow by USD 663.7 million from 2024-2028, Increase in incidence and prevalence of amyotrophic lateral sclerosis to boost the market growth, Technavio - Yahoo Finance

How Are Things Looking For NeuroSense Therapeutics Ltd (NASDAQ: NRSN) For The Short Term? - Stocks Register

Stock Market Recap: NeuroSense Therapeutics Ltd (NRSN) Concludes at 0.73, a -3.75 Surge/Decline - The Dwinnex

NeuroSense Therapeutics Ltd’s Mixed Bag: Down -13.90% in 6 Months, Down -18.79% in 30 Days - The InvestChronicle

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 14.3% in June - Defense World

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update - Defense World

NeuroSense Therapeutics Ltd (NRSN) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle

NeuroSense reports positive ALS study results, eyes FDA talks - Investing.com

NeuroSense reports positive ALS study results, eyes FDA talks By Investing.com - Investing.com UK

NeuroSense Therapeutics Ltd. Announces Additional Positive Results from its 12-Month PARADIGM Phase 2b Study of PrimeC in ALS Patients - Marketscreener.com

NeuroSense Reveals Breakthrough ALS Treatment Results - TipRanks

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression - Morningstar

NeuroSense Therapeutics shares positive results of lead candidate in ALS - PharmaTimes

Quarterly Metrics: Quick and Current Ratios for NeuroSense Therapeutics Ltd (NRSN) – DWinneX - The Dwinnex

NeuroSense Shareholders Approve Key Resolutions - TipRanks

NeuroSense Therapeutics : Annual Meeting of Shareholders Form 6 K - Marketscreener.com

This cheap biotech offers investors a play on ALS if trial data impresses - MarketWatch

ALS treatment PrimeC slows disease progression by 36% phase 2b trial results show - OutSourcing-Pharma.com

Views of Wall Street's Leading Experts on NeuroSense Therapeutics Ltd – Sete News - SETE News

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug - Quantisnow

In ALS, Phase II data show two drugs could be better than one - The Pharma Letter

Analyzing NRSN’s current quarter earnings projections - US Post News

Ähnlich wie NRSN